DiaMedica Therapeutics Inc.
DMAC
$5.42
-$0.19-3.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.28% | 28.99% | 36.63% | 27.78% | 20.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.71% | 9.43% | 31.24% | 42.02% | 41.86% |
| Operating Income | -28.71% | -9.43% | -31.24% | -42.02% | -41.86% |
| Income Before Tax | -30.31% | -10.63% | -37.45% | -50.49% | -49.71% |
| Income Tax Expenses | 16.67% | 11.11% | -14.29% | -14.29% | -14.29% |
| Earnings from Continuing Operations | -30.30% | -10.63% | -37.39% | -50.40% | -49.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.30% | -10.63% | -37.39% | -50.40% | -49.62% |
| EBIT | -28.71% | -9.43% | -31.24% | -42.02% | -41.86% |
| EBITDA | -28.75% | -9.44% | -31.17% | -42.22% | -41.86% |
| EPS Basic | -3.78% | 9.70% | -18.32% | -33.23% | -32.57% |
| Normalized Basic EPS | -3.83% | 9.64% | -18.45% | -33.37% | -32.59% |
| EPS Diluted | -3.78% | 9.70% | -18.32% | -33.23% | -32.57% |
| Normalized Diluted EPS | -3.83% | 9.64% | -18.45% | -33.37% | -32.59% |
| Average Basic Shares Outstanding | 25.56% | 22.45% | 16.09% | 12.84% | 12.87% |
| Average Diluted Shares Outstanding | 25.56% | 22.45% | 16.09% | 12.84% | 12.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |